Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism
Authors:
- P. EvenepoelPEP. Evenepoel
- J. CunninghamJCJ. Cunningham
- S. FerrariSFS. Ferrari
- M. HaarhausMHM. Haarhaus
- M.K. JavaidMJM.K. Javaid
- M.-H. Lafage-ProustMLM.-H. Lafage-Proust
- D. Prieto-AlhambraDPD. Prieto-Alhambra
- P.U. TorresPTP.U. Torres
- J. Cannata-AndiaJCJ. Cannata-Andia
- On Behalf Of The European Renal Osteodystrophy (Eurod) WorkgroupOWOn Behalf Of The European Renal Osteodystrophy (Eurod) Workgroup
- an initiative of the CKD-MBD working group of the ERA-EDTAAEan initiative of the CKD-MBD working group of the ERA-EDTA
- the committee of Scientific Advisors and National Societies of the IOFTIthe committee of Scientific Advisors and National Societies of the IOF
- 15 June 2021
- journal article
- review article
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (12) , 2397-2405
Abstract
The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) CKD-MBD working group, in collaboration with the Committee of Scientific Advisors of the International Osteoporosis Foundation, published a position paper for the diagnosis and management of osteoporosis in patients with CKD stages 4–5D (eGFR < 30 ml/min 1.73 m2). The present article reports and summarizes the main recommendations included in this 2021 document. The following areas are reviewed: diagnosis of osteoporosis; risk factors for fragility fractures; fracture risk assessment; intervention thresholds for pharmacological intervention; general and pharmacological management of osteoporosis; monitoring of treatment, and systems of care, all in patients with CKD stages 4–5D. Guidance is provided for clinicians caring for CKD stages 4–5D patients with osteoporosis, allowing for a pragmatic individualized diagnostic and therapeutic approach as an alternative to current variations in care and treatment nihilism.Keywords
This publication has 53 references indexed in Scilit:
- Bone Microarchitecture in Hemodialysis Patients Assessed by HR-pQCTClinical Journal of the American Society of Nephrology, 2011
- Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2010
- Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial dataBMJ, 2009
- Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns StudyKidney International, 2006
- Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2006
- Cortical PQCT Measures Are Associated With Fractures in Dialysis PatientsJournal of Bone and Mineral Research, 2006
- Effects of short‐term alendronate on bone mineral density in haemodialysis patientsNephrology, 2005
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994